Acquisition expands MSA's Detection solutions and adds new capabilities in the gas analysis and process safety markets With annual revenue of approximately $55 million, M&C TechGroup is highly ...
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by the aggregation of alpha-synuclein in the brain. Now, scientists have developed a radioligand that facilitates the ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...